We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > MaxCyte

News List

APEIRON, MaxCyte Enter Licensing Agreement for APN401 contractpharma
July 10, 2020
Will use MaxCyte’s ExPERT platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming trials.
Precision, MaxCyte Enter Clinical Agreement contractpharma
November 19, 2018
Precision BioSciences (Precision) and MaxCyte have entered into a non-exclusive, clinical and commercial license agreeme
Precision, MaxCyte Enter Clinical Agreement contractpharma
November 18, 2018
Allows Precision to use MaxCyte's Flow Electroporation® technologies to robustly deliver ARCUS genome-editing technology
CRISPR and MaxCyte sign licensing deal for cancer therapies pharmaceutical-technology
November 13, 2018
Swiss gene editing firm CRISPR Therapeutics has signed a non-exclusive commercial licence agreement with US-based drug maker MaxCyte for the development of new immuno-oncology therapies.